AZRX News

AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, raised $5 million by offering 0.96 million shares at $5.50. AzurRX Biopharma plans to list on the Nasdaq under the symbol AZRX. WallachBeth Capital and Network 1 Financial Securities acted as lead managers on the deal....read more

AzurRX Biopharma, which is developing non-systemic biologics for gastrointestinal disorders, again lowered the proposed deal size for its upcoming IPO on Wednesday. The Brooklyn, NY-based company now plans to raise $6.6 million by offering 1.2 million shares at a price of $5.50. The company had previously filed to offer 1.7 million shares at a range of $6 to $8, and before that...read more

After four weeks without a single IPO, the US IPO market is back from its annual August pause. Four deals are on the IPO calendar to raise $690 million in the week ahead, including: • The first energy IPO in over a year, an MLP with a 7.5% annualized yield • A VC-backed...read more

The week's leading IPO is a $250 million blank check company, a clear sign that the dog days of summer have taken hold in the US IPO market. Strong returns from recent IPOs indicate an open market when activity resumes in September. The Renaissance IPO Index was up 1.5% in the past week, and has gained 31% since its low in mid-February. The S&P 500 recently hit an...read more